Randomised trial comparing low-dose cisplatin and chlorambucil with low-dose cisplatin, chlorambucil, and doxorubicin in advanced ovarian carcinoma.
Ninety-eight patients with advanced ovarian cancer took part in a prospective, randomised trial comparing low-dose cisplatin and chlorambucil with low-dose cisplatin, chlorambucil, and doxorubicin. After 4 years response rates (greater than 50%) and proportion of complete remissions (28%) were similar in both groups. Median duration of remission was longest in the complete remitters, being 31 months in those having cisplatin and chlorambucil, and 24 months in those having doxorubicin as well.